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Bronchopulmonary dysplasia (BPD) is a chronic lung disease that predominantly affects 
prematurely born infants. Initially, BPD was described in infants who had suffered severe 
respiratory failure and required high pressure, mechanical ventilation with high concen-
trations of supplementary oxygen. Now, it also occurs in very prematurely born infants 
who initially had minimal or even no signs of lung disease. These differences impact 
the nature of the lung function abnormalities suffered by “BPD” infants, which are also 
influenced by the criteria used to diagnose BPD and the oxygen saturation level used to 
determine the supplementary oxygen requirement. Key also to interpreting lung function 
data in this population is whether appropriate lung function tests have been used and 
in an adequately sized population to make meaningful conclusions. It should also be 
emphasized that BPD is a poor predictor of long-term respiratory morbidity. Bearing in 
mind those caveats, studies have consistently demonstrated that infants who develop 
BPD have low compliance and functional residual capacities and raised resistances in the 
neonatal period. There is, however, no agreement with regard to which early lung function 
measurement predicts the development of BPD, likely reflecting different techniques were 
used in different populations in often underpowered studies. During infancy, lung function 
generally improves, but importantly airflow limitation persists and small airway function 
appears to decline. Improvements in lung function following administration of diuretics or 
bronchodilators have not translated into long-term improvements in respiratory outcomes. 
By contrast, early differences in lung function related to different ventilation modes have led 
to investigation and demonstration that prophylactic, neonatal high-frequency oscillation 
appears to protect small airway function.
Keywords: bronchopulmonary dysplasia, prematurity, resistance, compliance, diuretics, bronchodilators, 
corticosteroids
introduction
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that predominantly affects prematurely 
born infants, but can occur in those born at term if they are subjected to high-inflation pressures. 
Initially, BPD was described in prematurely born infants who often had suffered severe respiratory 
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failure and required high pressure, mechanical ventilation with 
high concentrations of supplementary oxygen, often coined old 
BPD. Such infants were not routinely exposed to either antenatal 
corticosteroids or postnatal surfactant. BPD now also occurs in 
very prematurely born infants who initially had minimal or even 
no signs of lung disease, the so-called new BPD (1). At postmor-
tem, infants with new rather than old BPD have less interstitial 
fibrosis, but an arrest in acinar development, resulting in fewer and 
larger alveoli (2). The chest radiograph (CXR) appearance of new 
BPD, that is small volume, hazy lung fields, is very different from 
the cystic abnormalities and interstitial fibrosis seen in “old” BPD. 
As a consequence, lung function abnormalities are likely to differ 
according to whether an infant is developing old or new BPD. The 
nature of the lung function abnormalities may also be influenced 
by the criteria used to diagnose BPD. These have included oxygen 
dependency at 28 days or 36 weeks post conceptional age (PCA) 
with or without radiological abnormalities. Nowadays, there is 
a consensus that infants should be diagnosed as having BPD if 
infants are oxygen dependent at 28 days after birth (3). They are 
then classified as suffering from mild, moderate, or severe BPD 
according to their respiratory support requirement at a later date 
(36  weeks PCA if born prematurely) (3) (Table  1). A further 
problem is that different levels of oxygen saturation have been 
used to determine the need for supplementary oxygen leading to 
wide variations in the occurrence of BPD (4). As a consequence, 
it is now recommended that an oxygen reduction test is used to 
determine whether supplementary oxygen is still required (5). 
Of note, lung function abnormalities as assessed by pulmonary 
function testing are not part of the current criteria to diagnose 
BPD, likely reflecting pulmonary function testing is not routinely 
available in all neonatal intensive care units (NICU).
Bearing in mind those caveats, an aim of this review is to 
describe lung function abnormalities in infants developing or with 
established BPD and how they change with increasing postnatal 
age during infancy. In addition, we will highlight if lung function 
testing in the NICU and during infancy gives added value. For 
example, do lung function test results so accurately predict BPD 
development that they could be used to identify infants who would 
benefit from intervention strategies or have improvements in 
lung function given an early indication of clinically efficacious 
interventions.
It, however, should be emphasized at the outset that a diagnosis 
of BPD is a poor predictor of ongoing pulmonary problems (6) 
and infants with and without BPD suffer respiratory morbidity 
at follow-up. In addition, certain randomized controlled trials 
TABLe 1 | BPd severity modified from Jobe and Bancalari (3).
Infants <32 weeks of gestational age are assessed at 36 weeks PCA or at 
discharge home, whichever came first
Infants born at 32 weeks of gestation or greater are assessed at 56 days 
postnatal age or discharge home, whichever came first
The severity of BPD being graded in both groups accordingly
 • mild BPD – breathing air
 • moderate BPD – requirement for <30% supplementary oxygen
 •  severe BPD – requirement for more that 30% oxygen and/or positive 
pressure ventilation or nasal continuous positive airway pressure (CPAP)
(RCTs), which have demonstrated a reduction in BPD, have not 
been associated with improvements in long-term respiratory 
outcome (7) and equally interventions influencing long-term 
respiratory morbidity were not associated with a reduction in 
BPD (8, 9).
Appropriate Lung Function Tests
Key to interpreting lung function data is whether an appropriate 
test has been used and whether the test has been applied robustly. 
In infants with evolving or established BPD, the techniques have 
strengths and weaknesses. Dynamic lung compliance measure-
ments do not require airway occlusions, which may be poorly 
tolerated in infants with respiratory distress. Esophageal pressure 
measurements, however, are required, which may not accurately 
reflect pleural pressure changes in prematurely born infants who 
have a floppy chest wall or in the presence of lung disease. Single 
breath mechanics do require airway occlusions and the underly-
ing assumptions are invalid if the respiratory system cannot be 
described as single-compartment model. The high resistance of 
small endotracheal tubes (10) may invalidate attempts to detect 
small changes in resistance in intubated infants. Assessments of 
functional residual capacity (FRC) by gas dilution or washout, 
can be applied in ventilated infants, but may underestimate the 
FRC if insufficient time is allowed for complete equilibration (11). 
Nitrogen washout with pure oxygen is impractical for ventilated 
infants receiving a high-fractional inspired oxygen concentration 
and inappropriate for infants at risk of retinopathy of prematurity. 
Inert gases such as helium and sulfur hexafluoride (SF6) avoid 
these problems. As a relatively heavy gas with low diffusivity, SF6 
has the additional advantage of being less susceptible than helium 
to leaks (12), especially those occurring around an uncuffed 
endotracheal tube. Certain centers, however, use shouldered 
tubes, which have been demonstrated to have minimal or no 
leak (13). The major strength of measuring lung volume using 
infant whole-body plethysmography is that the total lung volume 
can be measured and hence, if used in conjunction with a gas 
dilution technique, can provide an assessment of hyperinflation 
and gas trapping (14). Systems are commercially available, but 
depend on electronic manipulation to close the pressure flow 
loop, which can result in erroneous results (15). A further dis-
advantage is that plethysmographs are not suitable for cot side 
measurements. In addition, the accuracy of plethysmographic 
measurements is dependent on rapid equilibration of pressures 
during respiratory efforts against occlusions, so that pressure 
changes at the airway opening reflect those in the alveoli (16). 
In the presence of severe airway obstruction, this may not occur, 
resulting in a phase lag between airway pressure and box volume, 
usually resulting in overestimation of lung volume (11). As 
infants actively elevate their end expiratory level, all lung volume 
measurements should be made during quiet, non-rapid eye move-
ment sleep (17). Respiratory impedance plethysmography (RIP) 
can provide information on respiratory rate and the degree of 
thoracoabdominal asynchrony. The interpretation of the results 
is dependent on sleep state and volume calibration is not possible 
in this population.
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Lung Function Abnormalities
Among infants with “old” BPD, increased resistance in the first 
week after birth and increased total respiratory and expiratory 
resistance with severe flow limitation, especially at low lung 
volumes at 28  days after birth was reported (18). More recent 
studies, which have included infants who usually have received 
surfactant, have demonstrated somewhat differing results. In a 
group of infants, the majority of whom had been given rescue 
surfactant, respiratory system resistance (Rrs) was abnormal at 
10 days after birth, but then there was progressive improvement 
to normal values (19). In a series in which infants were given 
prophylactic surfactant and exposed to antenatal steroids, Rrs 
differed significantly between those who did and did not develop 
BPD on day three, but not at 14 days after birth (20).
Compliance is initially low in infants destined to develop 
BPD. In one series of ventilated infants, compliance of the 
respiratory system (Crs), using the single breath technique, was 
50% of predicted at 10 days of age (19). Interestingly, there was 
a positive correlation (r =  0.8, p <  0.001) between those Crs 
results and maximal flow at FRC (Vmax
¢  FRC) using the forced 
expiratory volume technique at 2 years of age. In the presence of 
low-saccular compliance, the highly compliant distal bronchial tree 
is preferentially over distended resulting in marked distortion of 
both distal and central areas during mechanical ventilation (21). 
The authors (19), therefore, postulated that in infants with very 
low lung compliance in the neonatal period, cyclic bronchiolar 
stretching during positive pressure ventilation resulted in terminal 
airway ischemia and necrosis and subsequent fibrosis and smooth 
muscle hypertrophy. Compliance and lung volume abnormalities 
may persist over the neonatal period. Comparison of FRC results 
from 16 BPD infants (oxygen dependent for more than 28 days) 
and 8 infants without BPD demonstrated the BPD group had lower 
FRCs at both 14 and 28 days (22). Similarly, serial measurements 
of Crs and FRC in 74 infants, median gestational age 30 weeks, 
35 of whom developed BPD (23 had moderate/severe BPD) 
demonstrated that those developing BPD, particularly moderate/
severe BPD had significantly lower Crs and FRC results throughout 
the neonatal period compared to those who did not develop BPD 
(20). CXR thoracic areas and FRC measurements assessed in 
the first 72 h after birth in 53 infants, median gestational age of 
28 weeks, also demonstrated lower FRCs in the BPD group, but the 
CXR thoracic areas were higher in the infants who subsequently 
developed BPD (oxygen dependency at 28 days) perhaps indicating 
gas trapping. The differences were particularly marked in infants 
who developed moderate/severe BPD (23). The reduced Crs in the 
neonatal period may be due to ongoing surfactant abnormalities, 
edema, and atelectasis. Similarly, the initial functional lung volume 
is likely reduced because of atelectasis.
During evolving BPD, there is gas trapping. FRC measured by 
plethysmography (FRCpleth) has been reported to be elevated 
in infants with BPD (24, 25) and in an early study FRCpleth was 
higher than FRC assessed by nitrogen washout (26). In established 
BPD, functional lung volume around term equivalent has been 
reported to still be significantly reduced compared, to data, 
from healthy term born infants both in an early (27) and in a 
more recent (24) study and associated with disturbed gas mixing 
(28). Those results appear pertinent to the present population 
of prematurely born infants who develop BPD. In a subsequent 
study (29), approximately 50% of the infants were exposed to 
antenatal steroids and 100% of those who developed moderate 
or severe BPD received surfactant. At term corrected, the severe 
BPD group had lower FRC, less efficient gas mixing, and higher 
specific conductance than those with mild and moderate BPD or 
the prematurely born controls. The infants with mild or moderate 
BPD infants also differed from the controls (29). BPD infants have 
also been shown to have significant increases in FRC, residual 
volume (RV), and RV/total lung capacity, which were more marked 
in those with recurrent wheeze, suggestive of hyperinflation and 
air-trapping (24). In a follow-up of prematurely born infants all 
born at <29 weeks of gestational age, two-thirds of whom had 
BPD, the degree of gas trapping significantly correlated with days 
of wheeze (30).
Results from a small study suggest that single photon emission 
computed tomography (SPECT) may provide additional informa-
tion about regional lung function in BPD infants (31). SPECT 
was used to measure the distribution of lung ventilation (V) and 
perfusion (Q) in 30 BPD infants at a median PCA of 37 weeks. 
An unsatisfactory V/Q match was not correlated with the time 
spent on supplemental oxygen or CPAP, but was significantly 
negatively correlated with the time spent on mechanical ventila-
tion. Increasing severity of BPD, however, was not consistently 
associated with the degree of V/Q mismatch.
Other lung function abnormalities in infancy suggest 
impairment of alveolar development after very premature birth. 
Pulmonary diffusing capacity and alveolar volume were assessed 
at 11.6  months of age using a single breath hold maneuver at 
elevated lung volume in 39 BPD infants (oxygen requirement 
at 36 weeks) and 61 term born controls. The BPD patients had 
reduced pulmonary diffusing capacity when adjusted for body 
length or alveolar volume (32).
Longitudinal Assessment
Early studies assessing serial lung function highlighted that lung 
compliance and FRC improved with increasing age (19, 27), such 
that by 2 years of age they had reached the normal range (19). In 
addition, during the first 2 years after birth, a relative increase 
in FRC using a gas dilution technique was reported (19). More 
recently, results were apparently at variance as assessment of 55 
sedated VLBW infants (29 with BPD, oxygen dependency at 
36 weeks PCA) at 50, 70, and 100 weeks of PCA demonstrated 
significantly lower tidal volume, minute ventilation, compliance, 
and FRC results in the BPD infants (33). Those differences, how-
ever, were no longer statistically significant once the results were 
normalized for body weight, which was significantly lower in the 
BPD group (33).
Airflow limitation, however, appears to be a persisting prob-
lem. An early report highlighted that lower airway obstruction 
persisted in infants with BPD who had severe disease as indicated 
by requirement for a tracheostomy (34). Longitudinal assessment 
demonstrated that, in infants with severe BPD, abnormalities in 
forced vital capacity (FVC) took longer to improve them eventually 
reaching the normal range by 3 years of age, but there was no 
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improvement in forced expiratory flow at 75% of vital capacity 
(FEF75) over the study period (34). In another study, 70% of 
BPD infants assessed at 2  years had low flow rates below 40% 
of that predicted, whereas lung volumes, Crs, and Rrs results 
were in the normal range (19). More recent results in the present 
population of prematurely born infants confirm those results (25, 
34). Assessment of 44 children with BPD (oxygen dependency 
at 28 days or 36 weeks PCA with CXR changes) highlighted that 
there were no improvements in Vmax
¢  FRC at 6, 12, and 24 months 
(35). In a longitudinal study, which examined infants at a PCA of 
58 weeks and then 33 weeks later, the group mean lung volumes 
and flows tracked at or near their previous values, that is, there was 
a lack of catch up growth. There were, however, improvements in 
lung function in those with above average growth (25).
Serial lung function measurements in infants with BPD have 
shown a decline in small airway function (as evidenced by assess-
ments of Vmax
¢  FRC) during the first year after birth (36). Similar 
changes in small airway function, however, have been reported in 
healthy, unsedated, prematurely born infants (37). Those findings 
emphasize the importance of using an appropriate control group 
when interpreting long-term effects of respiratory disease or 
management strategies in the neonatal period.
Prediction of BPd
Initial studies focused on compliance and resistance results with 
differing results. In certain studies, resistance, but not compli-
ance, results were predictive of BPD development. One study, 
however, included only 20 infants who had required mechanical 
ventilation for at least 3 days; 8 developed BPD (supplementary 
oxygen for longer than 28 days) (38). In a study of 46 infants with 
a birth weight <1.0 kg, those who subsequently developed BPD 
had significantly higher Rrs, but not Crs, at 1 week and Rrs was 
significantly higher in those with evolving BPD throughout the 
neonatal period (39). In another study, Rrs but not Crs before 
surfactant therapy was associated with an increased risk of BPD. 
Areas under receiver operator characteristic (ROC) curves were 
reported and demonstrated that Rrs performed similarly to 
gestational age and birth weight (40).
By contrast, other studies have demonstrated compliance rather 
than resistance was predictive of BPD development. Dynamic 
compliance, assessed using flow measurements from a pneumo-
tachograph related to mean airway pressures in 47 infants mean 
gestational age of 30 weeks in the first 3 days after birth, was sig-
nificantly lower in those who developed BPD, which was diagnosed 
using radiological criteria (41). In a subsequent study, an occlusion 
technique was used to determine appropriate esophageal balloon 
placement and longitudinal assessment over the first month was 
made on 143 infants with a gestational age of 27–30 weeks. The 
model, which included gestational age and dynamic pulmonary 
compliance, had the highest positive predictive accuracy (100%) 
for BPD (the need for supplemental oxygen at 4 weeks of age), 
whereas the predictive value of total pulmonary resistance was 
minimal (42). In 39 ventilated infants with a mean gestational 
age 26–28 weeks, the predictive ability of the results of the inter-
rupter technique was compared to respiratory mechanics results 
obtained during mechanical ventilation. Dynamic compliance of 
the respiratory system on day 1, birth weight and gestational age 
were all significantly lower in the BPD infants (BPD diagnosed if 
the infant developed lung disease in the first week after birth, was 
oxygen dependent at 28 days of age and developed characteristic 
chest x-ray changes), but there were no significant differences in 
the interrupter technique results. Dynamic compliance of the 
respiratory system was a better independent predictor of BPD 
development than gestational age or birth weight (43). More 
recently, among 52 prematurely born infants who were ventilated 
for more than 72  h and had received a single dose of porcine 
surfactant, initial compliance results did not differ between infants 
who went on to develop mild or severe BPD, but at days 7 and 10 
the “severe” group had significantly poorer compliance results. 
BPD was diagnosed as a requirement of supplementary oxygen 
at 28 days to maintain oxygen saturation above 95%; the severity 
of BPD was determined by the CXR score. Compliance but not 
resistance on days 7 and 10 were predictive of severe BPD (44).
In other studies, neither compliance nor resistance results 
were predictive of BPD development (45, 46). In a study of 
104 ventilator-dependent infants, with a mean gestational age 
27–30  weeks, respiratory mechanics were measured using an 
airway occlusion technique between 6 and 48 h after birth and 
corrected for body length. Birth weight, but not respiratory system 
mechanics, predicted BPD development (supplemental oxygen 
requirement 28 days after birth) (45). In a series of 58 infants who 
had RDS, compliance and resistance results were assessed using 
a commercially available system. BPD was diagnosed as oxygen 
supplementation, respiratory distress, and an abnormal CXR at 
28 days. Neither lung compliance nor pulmonary resistance on 
days 1–4 predicted BPD, but gestational age and a ventilatory index 
on day 3 (ventilator frequency × maximum inspiratory pressure) 
were predictive (46).
It is not possible to conclude from the above studies whether 
assessment of lung mechanics is helpful in predicting BPD devel-
opment. The discrepancy in the results likely reflects that different 
techniques were used in different populations. Few of the above 
studies included a sample size calculation and thus there may have 
been both type I and II errors.
More recent studies have investigated whether assessment of 
FRC might be predictive of BPD. In 100 infants with a median 
gestational age 28 weeks and ventilated within 6 h of birth, FRCHe 
≥19 ml/kg and a low gestational age in the first 48 h were more 
accurate predictors of BPD at 28 days than Crs or Rrs. Indeed, if 
only the 50 infants whose gestational age was ≤28 weeks of gesta-
tion were considered, a low FRC on day 2 was the best predictor 
of BPD development (47). Subsequently, the results of FRC and 
Crs on days 3 and 14 after birth were compared to a marker of 
inflammation, end-tidal carbon monoxide (ETCO). Seventy-eight 
infants with a median gestational age of 29 weeks were assessed; 
39 developed BPD (oxygen dependency at 28 days); a sample size 
calculation was given. Gestational age, birth weight, ETCO, FRC, 
and Crs results on days 3 and 14 differed significantly between 
those who did and did not develop BPD. Multifactorial logistic 
analysis, however, demonstrated only birth weight and ETCO 
levels on day 14 were significant predictors of BPD with an area 
under the ROC curve of 0.97. Those ETCO results indicate ongoing 
inflammation in infants developing BPD (48).
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Response to Therapies
Lung function tests have been used to assess the response to 
therapies in infants with evolving or established BPD. Variable 
and often conflicting results have been reported, which reflects the 
use of different techniques, some of which were inappropriate in 
this age group, lack of a sample size, or an inappropriate sample 
size based on too optimistic a view of the likely effect. A further 
problem in interpreting the results are that many of the studies 
were reported more than 20  years ago and, therefore, include 
infants not exposed to antenatal steroids or postnatal surfactant, 
which could have affected their response to the intervention. More 
importantly, reported changes in lung function results were not 
always accompanied by a change in clinical status or affected 
longer-term outcome.
diuretics
Bronchopulmonary dysplasia infants often are poorly tolerant of 
fluid loads with excessive weight gain on standard fluid regimens. 
As a consequence, diuretics are frequently prescribed but have 
short- and long-term side-effects including electrolyte disturbance 
and nephrocalcinosis. It is, therefore, important to determine if 
they are having a positive effect. Early results demonstrated that 
administration of frusemide acutely increased lung compliance 
and reduced airway resistance (49, 50) was associated with a reduc-
tion in ventilator requirements (51) and transient improvements 
in blood gases (49). A systematic review, however, demonstrated 
that in prematurely born infants <3  weeks of age, frusemide 
administration had either inconsistent or no detectable effects (52). 
In addition, in 16 spontaneously breathing infants with postnatal 
ages ranging from 4 to 35 weeks, a single dose of frusemide was 
associated with improvement in pulmonary compliance but not 
blood gases or resistance. Furthermore, a 6- to 10-day course was 
associated with improvement in compliance and resistance (53), 
but better oxygenation was only achieved in 6 of the 16 infants.
Nebulized frusemide has been given with the hope that this 
would improve respiratory function while avoiding the systemic 
complications. In a study of eight ventilated infants with a mean 
postnatal age of 33 days, the effects of 0.1, 0.25, 0.5, and 1.0 mg/
kg of nebulized frusemide were assessed. A dose of 1 mg/kg was 
associated with a 28% improvement in pulmonary resistance and 
a 51% improvement in pulmonary compliance at 1 h; the effects 
lasted for least 4 h. A systematic review demonstrated a significant 
improvement in tidal volume after 1 and 2 h, but no improvement 
in compliance at either time point (54).
Due to the side-effects of frusemide, infants who require 
chronic diuretic therapy are often changed to chlorothiazide 
and spironolactone. It had been suggested that the combination 
improved the outcome of babies with severe BPD (55). In a rand-
omized, double blind, crossover trial, the effects of oral diuretics 
(chlorothiazide 20 mg/kg/dose and spironolactone 1.5 mg/kg/
dose) given twice daily for a week were compared to placebo 
(56). The mean airway resistance, specific airway conductance, 
and dynamic compliance improved significantly, but only 
10 infants were included in the study. In a further randomized 
trial (57), spironolactone and chlorothiazide were compared 
to placebo in 43 oxygen dependent BPD infants. Infants in the 
treatment group only had improvements in dynamic pulmonary 
compliance and airway resistance and, at 4 weeks after study 
entry, required less supplementary oxygen than the placebo 
group. There were, however, no significant differences in the 
pulmonary function test results after discontinuation of treat-
ment, nor in the total number of days supplementary oxygen 
was required between the two groups. Orally administered 
diuretics (chlorothiazide and spironolactone) in combination 
with theophylline have been demonstrated to have an additive 
positive effect on dynamic compliance, but no effect on clinical 
outcomes were reported (58).
Bronchodilators
Inhaled bronchodilators have been reported to improve 
pulmonary resistance, dynamic compliance, and transcutane-
ous blood gases when administered to ventilated babies with 
BPD at approximately 1 month of age (59) and reduce airway 
resistance in infants with BPD at term (60–62). Intravenously 
administered salbutamol (30  μg/kg) in six infants aged 
between 54 and 105 days resulted in an improvement in res-
piratory system compliance and resistance using the occlusion 
technique, but there was no correlation between salbutamol 
serum concentration and pulmonary function changes (63). 
Comparison of the effectiveness of aerosol and intravenous 
delivery of salbutamol was made in eight ventilator-dependent 
infants in randomized order; there were similar improvements 
in pulmonary mechanics with the two delivery methods (64). In 
a comparison of different inhalation devices in infants during 
unassisted breathing as well as in a group of ventilated infants 
(65, 66), it was reported that both Crs and Rrs were sensitive 
indicators of a bronchodilator effect. Interpretation of those 
data is, however, limited because the studies were performed 
prior to standardization of the technique and intra-individual 
variability was not reported.
Synergism was reported between ipratropium bromide (IB) 
and salbutamol in improving pulmonary mechanics in ventilated 
infants for up to 1–2 h after administration (67). In 10, ventilator-
dependent infants, mean age 25 days, various dose of IB (75, 125, 
and 175 μg) plus 0.04 mg salbutamol were compared to placebo. 
Rrs and Crs were measured by the single breath occlusion 
technique. The greatest decline in Rrs (mean 26%) was seen after 
175 μg IB with salbutamol. The authors, therefore, concluded that 
muscarinic receptors contribute to the increased bronchomotor 
tone of infants with BPD (67). No synergy, however, was shown 
between metaproterenol and atropine with lung function returning 
to baseline after both treatments (68).
All of the above studies were undertaken more than 20 years 
ago, there were no sample size calculations and no long-term 
benefits reported. As a consequence, in the present population of 
premature infants, diuretics should only be given to treat incipi-
ent heart failure in infants with evolving or established BPD and 
stopped as soon as that problem ceases. Equally, bronchodilators 
should only be administered to treat troublesome wheeze and 
continued if the administration is associated with a reduction in 
respiratory support requirements. Administration should be via 
a metered dose inhaler and spacer rather than a nebulizer, as the 
nebulizing fluid can cause bronchoconstriction (69).
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dexamethasone
The efficacy of dexamethasone to prevent and treat BPD has 
been tested in many RCTs. Unfortunately, although systemically 
administered steroids have many positive effects, they have short- 
and long-term adverse effects. As a consequence, attention has 
been given to assessing the response to lower doses and inhaled 
steroids. A 1-week tapering course of dexamethasone starting at 
0.5 mg/kg/day given at 7–14 days of age in ventilator dependent, 
VLBW infants increased pulmonary compliance and decreased the 
incidence of BPD at 36 weeks PCA (70). In a subsequent study, 
the effectiveness of that dose (total dose 2.35 mg/kg) compared 
to a lower dose (total dose 1 mg/kg) was compared. FRC using a 
nitrogen washout technique and Crs by an occlusion technique 
were measured in infants at a mean age of 11 days. The sample 
size was powered to detect that the increase in FRC in the lower 
dose group would be more than 10% smaller than in the higher 
dose group. No significant differences were shown (71). In a RCT, 
10 days of dexamethasone were compared to 100 μg qds per day 
of budesonide in 40 infants with a median postnatal age 27 days. 
The study was powered to detect a difference of 7% in the inspired 
oxygen requirement 1 week after starting therapy. After 36 h, only 
the systemic group had significant reductions in the inspired 
oxygen concentration and Crs and at 1 week the systemic group 
had significantly better results than the inhaled group (72).
Respiratory support
Lung function testing has been used to compare the acute and 
longer-term efficacy of respiratory support techniques. For 
example, in a randomized crossover study, proportional assist 
ventilation (PAV) and assist control ventilation (ACV) were exam-
ined in infants with evolving BPD. When on PAV the infants had 
superior respiratory muscle strength and a lower work of breathing 
and this was associated with better oxygenation (73). Follow-up 
studies assessing the efficacy of ventilation modes demonstrate the 
importance of which lung function technique was employed. In a 
follow-up study of an RCT, no advantage of HFO over conventional 
ventilation (CMV) was reported with respect to lung function at 
1 year corrected, but small airway function was only assessed by 
evaluation of gas trapping (74). In another study, Vmax
¢  FRC was 
assessed at 6 and 12 months in infants who developed BPD. Those 
who were initially supported by CMV showed the expected decline 
in small airway function, but this was not seen in those seen in the 
HRO group. As a consequence, at 12 months, the HFO group had 
superior lung function (75). The results of that non-randomized 
study suggested that HFO might protect small airway function. 
Follow-up at 11–14 years of children who had been entered into 
a neonatal RCT of prophylactic HFO has subsequently proved 
that hypothesis (9).
conclusion and Future directions
•	 Infants who develop BPD have low compliance and lung 
volumes and elevated resistances in the neonatal period.
•	 During infancy, lung function generally improves, but airflow 
limitation persists and small airway function declines.
•	 Improvements in lung function following administration of 
diuretics or bronchodilators have not translated into long-
term improvements in respiratory outcomes, but assessment 
at follow-up has demonstrated neonatal high-frequency 
oscillation appears to protect small airway function.
•	 Further investigation should be undertaken to determine 
whether a lung function assessment accurately predicts 
chronic respiratory morbidity and hence prophylactic 
interventions can be appropriately targeted.
•	 Lung function assessment at follow-up should be incorpo-
rated into all neonatal RCTs, which are aimed at improving 
respiratory outcome.
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